Genenta Science (GNTA) CEO receives stock options for 100,000 ADSs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Genenta Science S.p.A. reported that Chief Executive Officer Pierluigi Paracchi received a grant of stock options for 100,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.

According to the grant terms, the options vest in equal monthly installments over three years beginning March 30, 2026, meaning the award becomes exercisable gradually rather than all at once. After this grant, Paracchi holds stock options covering 100,000 ADSs directly under this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Paracchi Pierluigi

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 100,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 100,000 options Underlying ADSs: 100,000 ADSs Exercise price: $0.63 per share +3 more

6 metrics

Options granted 100,000 options Stock Option (right to buy) award to CEO

Underlying ADSs 100,000 ADSs American Depositary Shares underlying the options

Exercise price $0.63 per share Conversion or exercise price of the options

Expiration date December 31, 2035 Option expiration

Grant date March 30, 2026 Beginning of monthly vesting period

Post‑grant derivative holdings 100,000 options Total derivative securities owned following transaction

Key Terms

Stock Option (right to buy), American Depositary Shares, exercise price, vest, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

American Depositary Shares financial

"underlying_security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"conversion_or_exercise_price: "0.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The stock options vest in equal monthly installments over three years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Chief Executive Officer financial

"officer_title: "Chief Executive Officer""

A chief executive officer (CEO) is the top leader of a company, responsible for making major decisions, setting goals, and guiding the organization’s overall direction. Think of the CEO as the captain of a ship, steering it toward success. Investors pay close attention to the CEO because their leadership and strategy can significantly influence the company's performance and future growth.

Form 4 Insider Transactions: What Each Field Means →

05/05/2026 - 09:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paracchi Pierluigi

(Last)

(First)

(Middle)

PIAZZA MARIA ADELAIDE DI SAVOIA 1

(Street)

MILAN

20129

(City)

(State)

(Zip)

ITALY

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.63	03/30/2026		A		100,000		⁽¹⁾	12/31/2035	American Depositary Shares	100,000	$0	100,000	D

Explanation of Responses:

1. The stock options vest in equal monthly installments over three years beginning March 30, 2026.

	/s/ Pierluigi Paracchi	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Genenta Science (GNTA) disclose in this Form 4 filing?

Genenta Science disclosed that CEO Pierluigi Paracchi received a grant of stock options for 100,000 American Depositary Shares. These options are part of his compensation and give him the right to buy shares at a fixed price if they vest and are later exercised.

How many Genenta Science (GNTA) stock options were granted to the CEO?

The CEO received stock options covering 100,000 American Depositary Shares. This award represents a right to acquire those ADSs at a preset exercise price in the future, subject to the vesting schedule and the stated expiration date of the options.

What is the exercise price and expiration date of the GNTA options granted?

The stock options have an exercise price of $0.63 per share and expire on December 31, 2035. This means the CEO can choose to buy shares at $0.63 any time after vesting and before the expiration date, if it is economically attractive.

How do the Genenta Science (GNTA) CEO’s options vest over time?

The options vest in equal monthly installments over three years beginning March 30, 2026. This monthly vesting schedule gradually makes portions of the 100,000-share award exercisable, encouraging longer-term alignment between the CEO and shareholders.

Is this Form 4 transaction a market purchase or sale of GNTA shares?

No, this filing reflects a grant of stock options as compensation, not a market purchase or sale. The transaction is coded as a grant or award acquisition, meaning the CEO received the right to buy shares later rather than trading shares in the open market.

How many GNTA options does the CEO hold after this transaction?

After this transaction, the CEO holds stock options covering 100,000 American Depositary Shares from this grant. The filing shows 100,000 derivative securities owned following the award, all held directly, reflecting this newly granted option position only.